BAY 11-7082

Novel inhibitor of cytokine-induced IkBa phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo: J.W. Pierce, et al.; J. Biol. Chem. 272, 21096 (1997) | Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells: N. Mori, et al.; Blood 100, 1828 (2002) | Sulfasalazine and BAY 11-7082 interfere with the nuclear factor-kappa B and I kappa B kinase pathway to regulate the release of proinflammatory cytokines from human adipose tissue and skeletal muscle in vitro: M. Lappas et al.; Endocrinology 146, 1491 (2005) | Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome: C. Juliana, et al.; J. Biol. Chem. 285, 9792 (2010) | A noble function of BAY 11-7082: Inhibition of platelet aggregation mediated by an elevated cAMP-induced VASP, and decreased ERK2/JNK1 phosphorylations: H.S. Lee, et al.; Eur. J. Pharmacol. 627, 85 (2010) | The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system: S. Strickson, et al.; Biochem. J. 451, 427 (2013) | The impact of alpha-Lipoic acid on cell viability and expression of nephrin and ZNF580 in normal human podocytes: U. Leppert, et al.; Eur. J. Pharmacol. 810, 1 (2017)